Relief of epigastric pain in nonulcer dyspepsia: controlled trial of the promotility drug cisapride.
In a randomized, double-blind, placebo-controlled study, 32 patients with nonulcer dyspepsia received 5 mg of cisapride or placebo three times daily for four weeks after a two-week run-in phase on placebo. Limited antacid use was allowed. Cisapride was superior to placebo in reducing the intensity of epigastric pain at two weeks (P = 0.03) and four weeks (P = 0.01). At the end of treatment, 82% of the cisapride-treated patients and 43% of the controls had no or only mild pain. Minor, gastrointestinal side effects were observed in two cisapride-treated patients and in one control.
De Nutte
N
N
Brugmann Hospital, Brussels, Belgium.
Van Ganse
W
W
Witterhulghe
M
M
Defrance
P
P
D000328:Adult; D000863:Antacids / Q000008:administration & dosage / Q000627:therapeutic use; D020117:Cisapride; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004415:Dyspepsia / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D010146:Pain / Q000188:drug therapy* / Q000209:etiology; D010880:Piperidines / Q000627:therapeutic use*; D011897:Random Allocation; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D013997:Time Factors
D000863:Antacids; D010880:Piperidines; D012702:Serotonin Antagonists; D020117:Cisapride